Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration

Safety and Therapeutic Effects of Orally Administered Akst4290 in Newly Diagnosed Neovascular Age-Related Macular Degeneration

“…2 Currently, blockade of vascular endothelial growth factor (VEGF), a potent proangiogenic cytokine, is the basis of primary pharmacological therapies for nAMD. 3,4 Intravitreally administered anti-VEGF therapies are the standard of care and have led to significant improvements in lesion morphology and central visual acuity. However, initial visual acuity improvements have been shown to diminish over time, 5,6 and the costs and frequency of treatment and monitoring are a substantial burden to patients, caregivers, ophthalmologists, and the healthcare system.…”